中国药业2026，Vol.35Issue(2)：23-27,5.DOI:10.3969/j.issn.1006-4931.2026.02.005
2023年至2024年昆明市药品零售企业检查问题分析及规范发展优化建议
Analysis of Inspection Issues and Optimization Suggestions for Standardized Development of Drug Retail Enterprises in Kunming from 2023 to 2024
摘要
Abstract
Objective To provide a reference for the standardized development of drug retail enterprises in Kunming.Methods A total of 9 079 defect items and 3 193 cases from drug retail enterprises in Kunming from 2023 to 2024 were included.The main distribution of defect items was analyzed,and correlation analysis and cluster analysis methods were used to identify key inspection items for standardized management of drug retail enterprises.The causes and potential impacts of defect problems were explored,and improvement suggestions were proposed.Results and Conclusion The defects from drug retail enterprises were mainly distributed in two aspects:drug quality management,personnel qualifications and training;personnel management,quality management and responsibilities,and document management were the key factors for standardizing quality management of drug retail enterprises;the main causes of defect problems were insufficient development of the own system of enterprise,imperfect regulatory system,and industry competition difficulties,which affected the medication safety of patients and the sustainable development of the industry.Strengthening the construction of quality management of enterprises,improving regulatory mechanisms and responsibility implementation,standardizing the industry competition order,and through multi-party collaboration and cooperation to promote the standardized development of drug retail enterprises in Kunming.关键词
药品零售企业/检查缺陷/规范发展/改进建议Key words
drug retail enterprise/inspection for defect/standardized development/improvement suggestion分类
医药卫生引用本文复制引用
田小权,曾文辉,黄文平..2023年至2024年昆明市药品零售企业检查问题分析及规范发展优化建议[J].中国药业,2026,35(2):23-27,5.基金项目
江西省药品监督管理局科研项目[2023G225、2022JS31]. （）
